Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts

Joseph M. Tuscano, Robert T. O'Donnell, Laird A. Miers, Linda A. Kroger, David L. Kukis, Kathleen R. Lamborn, Thomas F. Tedder, Gerald L. DeNardo

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Fingerprint Dive into the research topics of 'Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of <sup>90</sup>Y-DOTA-peptide-Lym-1 in lymphoma xenografts'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences